Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Reportedly Weighs Listing of Newly-Created Vaccines Unit

12/03/2021 | 03:08pm EST


ę MT Newswires 2021
All news about ASTRAZENECA PLC
04:38aImfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tr..
AQ
03:49aAstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Sta..
MT
02:59aAstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
DJ
01/18AstraZeneca's Liver Cancer Combo Extends Survival by Three Years in Late-Stage Study
MT
01/18AstraZeneca's Biliary Tract Cancer Combo Cuts Death Risk in Late-Stage Trial
MT
01/18Gates, Wellcome pledge $150 mln each to pandemic preparedness group
RE
01/18IMFINZI« (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line..
BU
01/18AstraZeneca Says Imfinzi Plus Chemotherapy Shows 20% Reduction in Risk of Death in Adva..
MT
01/18IMFINZI« (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanc..
BU
01/18ASTRAZENECA : Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line un..
PU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 100 M - -
Net income 2021 2 714 M - -
Net Debt 2021 24 811 M - -
P/E ratio 2021 54,4x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,78x
EV / Sales 2022 4,74x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 118,68 $
Average target price 138,63 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC0.56%183 633
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992